Removing immune 'brake' improves CAR T-cell therapy for pediatric bone cancer

Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma. There is a great clinical need for new therapies for childhood osteosarcoma, for which there are very few effective treatments for relapsed disease. The approach improved the cells' ability to control osteosarcoma growth and prevent metastasis to the lungs in preclinical models. The findings support the development of an early-phase clinical trial and were published today in Cell Reports Medicine.

Read it at Medical Xpress ↗

← Front page